Chief Executive Officer
Tim Collard is the Chief Executive Officer of PGTx Limited and is responsible for the overall management and operations of the company. Tim has more than 40 years’ experience in the global pharmaceutical and biotechnology industries. In 1975 he started his career working with Connaught Laboratories supplying human vaccines to the Hong Kong government and was also involved in development of Connaught’s veterinary vaccines. In 1977 he was recruited by Califas, a China-based consultancy, where he negotiated the first Sino-US joint manufacturing contract in the Chinese healthcare industry and preliminary joint venture agreements between Squibb and the Chinese government.
In 1980 Tim joined Solvay as Far East Director for Solvay’s Biochem Products division, a joint venture with the Pasteur Institute, which developed human and agricultural biologicals. In 1987 he became General Manager, Far East, of British biopharmaceuticals company Porton International where he established marketing, distribution, and local R&D in Asia for human vaccines and biopharmaceuticals, including Porton’s botulinum toxin for treatment of neurological diseases.
In 1993, Tim served as Vice President of Lotus Healthcare Corporation, a manufacturer of oral controlled-release morphine and dihydrocodeine in China. He was responsible for business development, sourcing of Chinese pharmaceutical raw materials, and all in-licensing and technology transfer. In 1997, he established Phoenix Lifesciences to provide transactional consultancy services to the biotechnology sector in Greater China and Southeast Asia. In this consulting capacity, Tim negotiated a “first mover” supply agreements for bulk antibiotics between a Chinese producer and British pharmaceutical companies. Tim continued to work on a variety of projects with local and multinational companies including AstraZeneca, Authentix, Aventis, bioMérieux, Proctor & Gamble, SciClone, and Xenova.
Tim holds a BS in biology from Bristol University in the United Kingdom.
Louis M. Bowen
Chairman and Chief Financial Officer
Louis Bowen, MBA, is the Executive Chairman and Chief Financial Officer of PGTx Limited. He also currently serves as the Executive Chairman and CFO of Pacific GeneTech Limited, an animal health biotech company he co-founded in 2009.
He also serves as the Chairman and CEO of Asia Capital Management Limited, a private investment banking company based in Hong Kong that he founded in 1994. Louis started his career with Citigroup in New York, before relocating to Hong Kong to establish the Citigroup corporate finance activities in Asia. Louis has overseen many investments and acquisitions in Asia across a range of industries including pharmaceuticals, primary care services, and medical diagnostics.
Louis has served on the boards of a number of companies during his professional career and currently serves on the Advisory Council of the Hong Kong University of Science and Technology Business School, The Dean’s Executive Advisory Board of the Walton School of Business at the University of Arkansas, the Board of Governors of the Wharton Alumni Association of Hong Kong and the Board of Advisors of the Arkansas World Trade Center.
Louis holds an MBA in Finance from the Wharton School and has a BA in Economics from the University of Arkansas.
Director, Business Development
Cindy Tsang, MBA, has over 15 years of broad international experience in corporate strategy and advisory, compliance consulting, and scientific R&D for multinational pharmaceutical corporations, major investment banks, consulting firms, and early stage companies.
Cindy joined PGT in 2013 from an advisory firm she founded where she assisted early stage healthcare companies in medical devices, diagnostics and healthcare IT with business planning, fundraising, and growth strategies development. Cindy held management positions as an Assistant Director in the quality and risk management group at Ernst & Young and previously an Associate at Morgan Stanley in Hong Kong. She also had prior experience as an investment banking analyst at a boutique Mergers and Acquisitions advisory firm in Chicago where she led commercial due diligence on potential investments for a life sciences venture fund.
Cindy began her career as a research scientist at Abbott Laboratories’ Pharmaceutical R&D division in Abbott Park, Illinois. She spearheaded a membrane protein purification project to support the use of structural biology in drug discovery efforts. Her work has been published in scientific journals.
Cindy holds an MBA in Finance from the University of Cambridge and a BS in Biochemistry from Seattle University.
Dr. Anna Obolensky
Director, Translational Research
Dr Obolensky is a microbiologist and immunologist with experience in pharmaceuticals, research institutions and private equity. She has extensive experience in intellectual property management, commercialisation, and research.
She started her career at Porton International, which commercialised drugs and vaccines originating from the British government’s Centre for Applied Microbiology and Research at Porton Down. Dr Obolensky established the company’s Hong Kong office to oversee clinical development and trials in Asia for novel products.
Following her work at Porton, Dr Obolensky completed a PhD in immunology. She then worked as an independent consultant advising companies and institutions on ways to evaluate, protect, and maximise their IP for commercialisation.
Later, Dr Obolensky served as Head of External Sciences for H2O Venture Partners, a private equity firm focused on early stage technologies. Since 2011, Dr Obolensky has worked as a consultant for the British Heart Foundation responsible for auditing BHF-funded scientists across 14 British universities.
Dr. Obolensky holds a PhD from Keble College, University of Oxford. She is a Fellow of the Royal Society of Medicine and a Member of British Society of Immunology.